Annals of Oncology 25 (Supplement 4): iv517–iv541, 2014
doi:10.1093/annonc/mdu356.22
supportive care
11
Medical Oncology, Pamukkale University School of Medicine, Denizli, TURKEY
Medical Oncology, Cukurova University Medical Faculty, Adana, TURKEY
Medical Oncology, Ataturk University, Erzurum, TURKEY
12
13
1501P
COMPARISON OF THE EFFICACY OF FILGRASTIM
(NEUPOGEN®) AND BIOSIMILAR FILGRASTIM
(LEUCOSTIM®) IN PATIENTS WITH
CHEMOTHERAPY-INDUCED NEUTROPENIA: A NATIONWIDE
OBSERVATIONAL STUDY
abstracts
Downloaded from http://annonc.oxfordjournals.org/ by guest on January 23, 2015
A. Sevinc1, M. Ozkan2, A. Ozet3, F. Dane4, B. Oksuzoglu5, A. Isikdogan6,
F. Ozdemir7, D. Uncu8, M. Gumus9, T. Evrensel10, A. Yaren11, O. Kara12,
S.B. TekIṅ 13
1
Medical Oncology Department, Gaziantep University Onkoloji Hastanesi,
Gaziantep, TURKEY
2
Medical Oncology, Erciyes University Medical Faculty M. Kemal Dedeman,
Oncology Hospital, Kayseri, TURKEY
3
Medical Oncology, Gazi University Faculty of Medicine, Ankara, TURKEY
4
Medical Oncology Department, Marmara University Hospital, Istanbul, TURKEY
5
Department of Medical Oncology, Ankara Dr. A.Y.Oncology Research and
Education Hospital, Ankara, TURKEY
6
Medical Oncology, Dicle University, Diyarbakir, TURKEY
7
Medical Oncology Dept., Karadeniz Technical UniversityMedical Faculty, Trabzon,
TURKEY
8
Medical Oncology, Ankara Numune Education and Research Hospital, Ankara,
TURKEY
9
Dept. Medical Oncology, Bezmialem Vakif University Hospital, Istanbul, TURKEY
10
Medıcal Oncology, Uludag University Medıcıne Faculty, Bursa, TURKEY
Aim: A biosimilar drug is an analogous drug of the biological licensed referenced drug.
In this cohort, we aimed to study the effectiveness of the biosimilar and origial
filgrastim in patients with chemotherapy-induced neutropenia.
Methods: There were 337 patients in the national observational study. Patients
receiving chemotherapy was enrolled in the study after neutropenia. Filgrastim, either
original or biosimilar, was used.
Results: The average age was 53.15 ± 14.10 years, the median was 55.0 (min:19-max:85)
years. There were 724 courses of drug application. 13.7% received one course of
chemotherapy (CT), 45.5% received two courses of CT, 27.4% received three courses of CT,
11.4% received four courses of CT, and the rest received five courses of CT. The avarage
neutrophil count was 0.4 before the filgrastim application and 3.0 afterwards. Biosimilar
filgrastim 30 was applied to 61.9%, original filgrastim 30 to 8.9%, and original filgrastim 48
to 29.2%. Recovery in four days was observed in 60.1% of the patients receiving biosimilar
filgrastim 30, 56.7% in original filgrastim 30, and 52.6% in original filgrastim 48. However,
there was no statistically significant difference in the neutropenia recovery periods for all of
the drugs (p > 0,05). There was also no statistically significant difference between biosimilar
filgrastim 30 vs. original filgrastim 30 in the recovery periods (p > 0.05).
Conclusions: The biosimilar drug should be compared with the original drug in
order to establish the same efficacy. The present study did not find any difference
between the biosimilar and original filgrastim in patients with
chemotherapy-induced neutropenia.
Disclosure: All authors have declared no conflicts of interest.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: [email protected]
Download

supportive care - Annals of Oncology